Aybuke Celik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Aybuke Celik has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Sandra Lindstedt
Department of Clinical Sciences, Lund University, Lund, Sweden
3 shared publications - Ahmet Dogan Ergin
Trakya Universitesi
2 shared publications - Burcu Uner
Department of Pharmaceutical and Administrative Sciences, University of Health Science and Pharmacy in St. Louis, St. Louis, USA
2 shared publications - Franziska Olm
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
2 shared publications - Gabriel Hirdman
Department of Cardiothoracic Surgery and Transplantation, Skåne University Hospital, Lund, Sweden
2 shared publications James D. McCully
Department of Cardiac Surgery, Boston Children's Hospital, Boston, MA, USA; Harvard Medical School, Boston, MA, USA
2 shared publications
Latest Publications
- Top Cited Papers
- 14 April 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (7) , 459-473
Therapeutic and mechanistic insights on mitochondrial transplantation in kidney disease
Acute kidney injury (AKI) and chronic kidney disease (CKD) are major contributors to global morbidity and mortality, with limited treatment options beyond supportive care. Mitochondrial dysfunction is a shared feature of both conditions, driving impaired energy production, oxidative stress and cell death. Owing to its reliance on oxidative phosphorylation, the kidney is especially vulnerable to ischaemia–reperfusion injury, a leading cause of AKI and a risk factor for long-term loss of kidney function. Persistent mitochondrial damage contributes to the transition from AKI to CKD, and strategies aimed at restoring mitochondrial health, therefore, have therapeutic potential. Here, we focus on mitochondrial transplantation, a therapeutic approach that delivers viable, respiratory-competent mitochondria to injured tissue to support recovery. Mitochondria for transplantation can be isolated from a variety of sources (autologous or allogeneic) without triggering an immune, autoimmune or inflammatory response, or a reaction to damage-associated molecular patterns. Isolated mitochondria can be delivered by intra-arterial injection, and, once in the target organ, they are rapidly integrated into the cells through endocytosis. Mitochondrial transplantation supports the restoration of mitochondrial function and associated signalling pathways, promoting enhanced organ function and cellular viability. Several preclinical studies have demonstrated improved kidney function, reduced inflammation and preserved mitochondrial structure following mitochondrial therapy in models of ischaemia.
- 14 April 2026
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 22 (7) , 459-473
Top Cited PapersTherapeutic and mechanistic insights on mitochondrial transplantation in kidney disease
Acute kidney injury (AKI) and chronic kidney disease (CKD) are major contributors to global morbidity and mortality, with limited treatment options beyond supportive care. Mitochondrial dysfunction is a shared feature of both conditions, driving impaired energy production, oxidative stress and cell death. Owing to its reliance on oxidative phosphorylation, the kidney is especially vulnerable to ischaemia–reperfusion injury, a leading cause of AKI and a risk factor for long-term loss of kidney function. Persistent mitochondrial damage contributes to the transition from AKI to CKD, and strategies aimed at restoring mitochondrial health, therefore, have therapeutic potential. Here, we focus on mitochondrial transplantation, a therapeutic approach that delivers viable, respiratory-competent mitochondria to injured tissue to support recovery. Mitochondria for transplantation can be isolated from a variety of sources (autologous or allogeneic) without triggering an immune, autoimmune or inflammatory response, or a reaction to damage-associated molecular patterns. Isolated mitochondria can be delivered by intra-arterial injection, and, once in the target organ, they are rapidly integrated into the cells through endocytosis. Mitochondrial transplantation supports the restoration of mitochondrial function and associated signalling pathways, promoting enhanced organ function and cellular viability. Several preclinical studies have demonstrated improved kidney function, reduced inflammation and preserved mitochondrial structure following mitochondrial therapy in models of ischaemia.
- Open Access
- 14 November 2025
- Published by Springer Nature in Research Square
Mitochondrial Therapy During Machine Perfusion Restores the Function of DCD Livers: A Cross-Circulation Evaluation for Transplant Suitability
Donation after circulatory death (DCD) has significantly increased the number of organs potentially available for transplantation. Livers are more vulnerable than most other solid organs to warm ischemia in the DCD process. The injury induced by warm ischemic time (WIT) is further exacerbated during cold ischemia and reperfusion, resulting in tissue damage caused by the production of reactive oxygen species. These are not only cytotoxic but also perpetuate mitochondrial dysfunction and cell death. To improve the utilization of livers from uncontrolled DCD (uDCD) or controlled DCD (cDCD) donors with prolonged WIT, new strategies to mitigate WIT must be developed.Ex vivo normothermic machine perfusion (NMP) has increased DCD organ utilization and improved the assessment of the viability of organs before transplantation. NMP could also serve as a platform for isolated treatment of organs prior to transplant. An innovative approach to mitigate organ injury is to treat damaged livers with mitochondrial transplantation (MTx). In this study, we tested the efficacy of xenogeneic mitochondrial administration to restore the function of porcine DCD livers with two hours of warm ischemia. DCD livers were explanted and connected to NMP, where mitochondrial transplantation was administered as a bolus dose in the portal vein and hepatic artery at the start of perfusion. After four hours of NMP, treated livers demonstrated a significant increase in bile production, improved bile quality, and restored cytoarchitecture.To further assess the transplantation suitability of these livers post-NMP, they were connected to cross-circulation (CC) with a recipient pig. After six hours of CC, untreated livers became oedematous, exhibited significant aspartate aminotransferase elevations in the bile, and showed cellular degeneration, including near-complete loss of Kupffer cells. In contrast, livers treated with MTx maintained function across CC and were comparable to healthy controls. These data validate the efficacy of MTx in restoring function in DCD livers exposed to prolonged ischaemic times, presenting a promising approach to expand the donor pool.
- 14 November 2025
- Published by Springer Nature in Research Square
Open AccessMitochondrial Therapy During Machine Perfusion Restores the Function of DCD Livers: A Cross-Circulation Evaluation for Transplant Suitability
Donation after circulatory death (DCD) has significantly increased the number of organs potentially available for transplantation. Livers are more vulnerable than most other solid organs to warm ischemia in the DCD process. The injury induced by warm ischemic time (WIT) is further exacerbated during cold ischemia and reperfusion, resulting in tissue damage caused by the production of reactive oxygen species. These are not only cytotoxic but also perpetuate mitochondrial dysfunction and cell death. To improve the utilization of livers from uncontrolled DCD (uDCD) or controlled DCD (cDCD) donors with prolonged WIT, new strategies to mitigate WIT must be developed.Ex vivo normothermic machine perfusion (NMP) has increased DCD organ utilization and improved the assessment of the viability of organs before transplantation. NMP could also serve as a platform for isolated treatment of organs prior to transplant. An innovative approach to mitigate organ injury is to treat damaged livers with mitochondrial transplantation (MTx). In this study, we tested the efficacy of xenogeneic mitochondrial administration to restore the function of porcine DCD livers with two hours of warm ischemia. DCD livers were explanted and connected to NMP, where mitochondrial transplantation was administered as a bolus dose in the portal vein and hepatic artery at the start of perfusion. After four hours of NMP, treated livers demonstrated a significant increase in bile production, improved bile quality, and restored cytoarchitecture.To further assess the transplantation suitability of these livers post-NMP, they were connected to cross-circulation (CC) with a recipient pig. After six hours of CC, untreated livers became oedematous, exhibited significant aspartate aminotransferase elevations in the bile, and showed cellular degeneration, including near-complete loss of Kupffer cells. In contrast, livers treated with MTx maintained function across CC and were comparable to healthy controls. These data validate the efficacy of MTx in restoring function in DCD livers exposed to prolonged ischaemic times, presenting a promising approach to expand the donor pool.
- 5 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1648-1658
Revitalizing donor organs: The potential of mitochondrial transplantation in heart and lung transplantation
- 5 July 2025
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (10) , 1648-1658
Revitalizing donor organs: The potential of mitochondrial transplantation in heart and lung transplantation
- Open Access
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 448-459
Xenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion
- 12 November 2024
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 44 (3) , 448-459
Open AccessXenotransplantation of mitochondria: A novel strategy to alleviate ischemia-reperfusion injury during ex vivo lung perfusion
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 19 (3) , 1-25
Elucidating the Signaling Pathways Involved in Erectile Dysfunction
Background: Erectile Dysfunction (ED) is a common sexual disorder among men aged 20 years and over. It is predominantly characterized by alterations in the key physiological pathways regulating erectile function, such as nitric oxide and Ras homolog gene family member A (RhoA)/Rho-associated protein kinase (ROCK). Beyond these pathways, multiple molecular signaling networks are involved in ED pathogenesis. Objective: This review aims todescribe the major signal transduction pathways that impact erectile function and contribute to the introduction of the pathogenesis of ED. Methods: A literature review of ED was performed from 2000 to 2023 using PubMed, Scopus, and Embase. “ED” and “related signaling pathway”, “molecular mechanisms” terms were used. Results: Further basic and clinical studies are required to define the underlying molecular mechanisms of ED. The signaling pathways that were not affected by phosphodiesterase type 5 inhibitors (PDE5i) may be the reason for the reduced efficacy of this first-line treatment option in a variety of conditions. Conclusion: There is still a need for a deeper description of the molecular mechanisms in terms of fibrosis, angiogenesis, apoptosis, inflammation, oxidative stress, autophagy, and hypoxia to identify new possible targets underlying the pathogenesis of ED. This comprehensive review expounds on the principal signaling pathways, offering valuable insights that may catalyze the development of innovative and enhanced therapies for managing ED.
- 1 November 2024
- Published by Bentham Science Publishers Ltd. in Current Signal Transduction Therapy
- Vol. 19 (3) , 1-25
Elucidating the Signaling Pathways Involved in Erectile Dysfunction
Background: Erectile Dysfunction (ED) is a common sexual disorder among men aged 20 years and over. It is predominantly characterized by alterations in the key physiological pathways regulating erectile function, such as nitric oxide and Ras homolog gene family member A (RhoA)/Rho-associated protein kinase (ROCK). Beyond these pathways, multiple molecular signaling networks are involved in ED pathogenesis. Objective: This review aims todescribe the major signal transduction pathways that impact erectile function and contribute to the introduction of the pathogenesis of ED. Methods: A literature review of ED was performed from 2000 to 2023 using PubMed, Scopus, and Embase. “ED” and “related signaling pathway”, “molecular mechanisms” terms were used. Results: Further basic and clinical studies are required to define the underlying molecular mechanisms of ED. The signaling pathways that were not affected by phosphodiesterase type 5 inhibitors (PDE5i) may be the reason for the reduced efficacy of this first-line treatment option in a variety of conditions. Conclusion: There is still a need for a deeper description of the molecular mechanisms in terms of fibrosis, angiogenesis, apoptosis, inflammation, oxidative stress, autophagy, and hypoxia to identify new possible targets underlying the pathogenesis of ED. This comprehensive review expounds on the principal signaling pathways, offering valuable insights that may catalyze the development of innovative and enhanced therapies for managing ED.
- 15 July 2023
- Published by Springer Nature in Medical Oncology
- Vol. 40 (8) , 1-9
Alpha-lipoic acid induced apoptosis of PC3 prostate cancer cells through an alteration on mitochondrial membrane depolarization and MMP-9 mRNA expression
Cancer has become an important cause of mortality and morbidity in the world. Over the past decades, biomedical research revealed insights into the molecular events and signaling pathways involved in carcinogenesis and cancer progression. Matrix metalloproteinases (MMPs) are a diverse family of enzymes that can degrade various components of the extracellular matrix and are considered as potential diagnostic and prognostic biomarkers for many cancer types and cancer stages. Recently, studies on the role of natural-origin active substances in the prevention of cancer development gained importance. Among them, the α-lipoic acid, which is commonly found in plants, displayed potent anti-proliferative effects on cancer cell lines. However, the effect of the compound on the induction of apoptosis and mRNA expression of MMPs in human prostate cancer cells remains unclear. The present study aimed to evaluate the anti-proliferative and apoptotic activity of α-lipoic acid in human PC3 prostate carcinoma cells considering different concentrations and exposure durations. The findings showed that, α-lipoic acid significantly decreased PC3 cell viability with an IC50 value of 1.71 mM at 48 h (p < 0.05). Additionally, the compound significantly increased Annexin-V binding in cells compared to control and induced a significant alteration in mitochondrial membrane potential and caspase levels (p < 0.05). Furhermore, the RT-PCR analyses have revealed that α-lipoic acid reduced MMP-9 mRNA expression in PC3 cells compared to the control (p < 0.05). In conclusion, this study highlights that α-lipoic acid induced apoptosis in human PC3 prostate cancer cells and inhibited the MMP-9 gene at the mRNA level, which is known to play a role in metastasis development.
- 15 July 2023
- Published by Springer Nature in Medical Oncology
- Vol. 40 (8) , 1-9
Alpha-lipoic acid induced apoptosis of PC3 prostate cancer cells through an alteration on mitochondrial membrane depolarization and MMP-9 mRNA expression
Cancer has become an important cause of mortality and morbidity in the world. Over the past decades, biomedical research revealed insights into the molecular events and signaling pathways involved in carcinogenesis and cancer progression. Matrix metalloproteinases (MMPs) are a diverse family of enzymes that can degrade various components of the extracellular matrix and are considered as potential diagnostic and prognostic biomarkers for many cancer types and cancer stages. Recently, studies on the role of natural-origin active substances in the prevention of cancer development gained importance. Among them, the α-lipoic acid, which is commonly found in plants, displayed potent anti-proliferative effects on cancer cell lines. However, the effect of the compound on the induction of apoptosis and mRNA expression of MMPs in human prostate cancer cells remains unclear. The present study aimed to evaluate the anti-proliferative and apoptotic activity of α-lipoic acid in human PC3 prostate carcinoma cells considering different concentrations and exposure durations. The findings showed that, α-lipoic acid significantly decreased PC3 cell viability with an IC50 value of 1.71 mM at 48 h (p < 0.05). Additionally, the compound significantly increased Annexin-V binding in cells compared to control and induced a significant alteration in mitochondrial membrane potential and caspase levels (p < 0.05). Furhermore, the RT-PCR analyses have revealed that α-lipoic acid reduced MMP-9 mRNA expression in PC3 cells compared to the control (p < 0.05). In conclusion, this study highlights that α-lipoic acid induced apoptosis in human PC3 prostate cancer cells and inhibited the MMP-9 gene at the mRNA level, which is known to play a role in metastasis development.